Skip to content
Welcome, thoughtbot's Giant Robots listeners!Start here
Pandemics and Biosecurity
3OCT

FAO costs drug-resistance inaction at $318bn

2 min read
13:42UTC

The FAO put a price on antimicrobial resistance on 3 June, projecting $318bn in cumulative livestock losses by 2040, about six times the cost of acting now.

ScienceDeveloping
Key takeaway

Pricing drug resistance as $318bn in lost production reaches ministries a death toll never moved.

The Food and Agriculture Organization (FAO), the UN's Rome-based agency for food and farming, put a price on inaction over AMR (antimicrobial resistance, the process by which bacteria stop responding to the drugs meant to kill them) on 3 June. Its report projects global antimicrobial use in livestock rising 30% by 2040 against a 2019 baseline, and cumulative livestock production losses reaching $318bn by 2040 under a high-resistance scenario⁠1. That $318bn runs about six times the cost of acting now.

May's adoption of the WHO Global Action Plan on AMR set a mortality target, a 10% cut in bacterial AMR deaths by 2030. FAO has now attached a balance-sheet figure to the alternative, routing the same problem through food-security economics to reach an audience that a death toll did not. The 6:1 inaction-to-action ratio is the lever, reframing mitigation spending as loss avoidance rather than public-health cost.

Cheap antibiotics keep crowded herds productive, so use climbs with demand for meat, and resistance follows the use, an unremarkable chain that the $318bn figure now prices. Pricing the loss in production rather than deaths is how the issue reaches the agriculture and finance ministries that control the antibiotics and that a public-health framing never reached.

Deep Analysis

In plain English

Farmers use antibiotics to keep livestock healthy and speed up animal growth. When antibiotics are used too frequently, bacteria evolve to resist them, making those drugs less effective for both animals and humans over time. This is called antimicrobial resistance, or AMR. FAO, the UN's food and agriculture body, published a report on 3 June estimating that unchecked AMR will cost the farming industry $318 billion in lost livestock production by 2040, as animals die from infections that should be treatable. Preventing that outcome would cost around one-sixth as much. The report argues that tackling antibiotic overuse in farming serves both economic and public health goals.

Deep Analysis
Root Causes

The projected 30% rise in livestock antimicrobial use to 2040 reflects a structural dependency: antibiotic prophylaxis compensates for suboptimal biosecurity in intensive production systems. The economic incentive structure rewards volume and speed of production over herd health investment, particularly in markets where veterinary drug regulation is weak or enforcement is absent.

The WHO GAP-AMR 2026-2036, adopted 23 May, sets a 10% reduction target in AMR-attributable deaths by 2030 , a human-health metric. The FAO report reframes AMR as a food-security and economic threat independent of that metric, addressing a different political constituency: agriculture ministries and development finance institutions that do not engage with WHO's public-health framing.

What could happen next?
  • Consequence

    FAO's $318bn figure provides an economic mandate for agriculture ministries to engage with the WHO GAP-AMR 2026-2036 (ID:3599) framework , translating a public-health target into a production-economics argument that reaches beyond health ministry budgets.

  • Risk

    The 30% projected rise in livestock antimicrobial use by 2040 is concentrated in regions with limited veterinary drug regulatory capacity, meaning the economic cost will fall disproportionately on small-scale farmers in lower-income countries who have the least ability to absorb it.

First Reported In

Update #6 · Ebola outbreak gets an R0, and a fork

FAO· 9 Jun 2026
Read original →
Different Perspectives
IGWG co-chair Tovar da Silva Nunes
IGWG co-chair Tovar da Silva Nunes
The Brazilian co-chair closed the eighth pathogen-sharing session on 18 September without an agreed annex text, the second session in a row to end that way. He presented the outcome as continued commitment, with adoption due at the World Health Assembly in May 2027.
Fraport
Fraport
The Frankfurt Airport operator has told staff to watch for fever, hessenschau reported, after six airport workers caught malaria. Germany does not require insecticide spraying of arriving aircraft cabins, and parasite genotyping to trace the source is due at the end of October.
European Centre for Disease Prevention and Control
European Centre for Disease Prevention and Control
ECDC reported the eight Frankfurt Airport malaria cases on 18 September and considers repeated arrivals of infected mosquitoes on aircraft likely. It has not ruled out local mosquitoes, and awaits genotyping due at the end of October.
Pan American Health Organization
Pan American Health Organization
PAHO counted 53,957 measles cases in the Americas by 19 September and is supporting Peru's response in Puno and Arequipa. It warns that October's Señor de los Milagros festivities and Pope Leo XIV's November visit could increase transmission.
Bangladesh Directorate General of Health Services
Bangladesh Directorate General of Health Services
The DGHS recorded 1,030 measles-related deaths and 172,720 suspected cases by 14 September, after a campaign that reached 19.75 million children. Its disease-control director, Halimur Rashid, said further vaccination rounds were expected within two weeks.
Minapharm
Minapharm
The Egyptian drugmaker and its Berlin subsidiary ProBioGen were awarded up to US$16.5m by CEPI on 27 August to take a Bundibugyo vaccine into a Phase 1 trial in Africa. Final manufacture is planned for Cairo, making it CEPI's first Bundibugyo candidate with an African producer.